David Colleran
Net Worth

Last updated:

What is David Colleran net worth?

The estimated net worth of Mr. David Colleran is at least $2,401,638 as of 11 Mar 2024. He owns shares worth $84,758 as insider and has received compensation worth at least $2,316,880 in Anika Therapeutics, Inc..

What is the salary of David Colleran?

Mr. David Colleran salary is $579,220 per year as Executive Vice President, Gen. Counsel & Corporation Sec. in Anika Therapeutics, Inc..

How old is David Colleran?

Mr. David Colleran is 53 years old, born in 1972.

What stocks does David Colleran currently own?

As insider, Mr. David Colleran owns shares in one company:

Company Title Shares Price per share Total value
Anika Therapeutics, Inc. (ANIK) Executive Vice President, Gen. Counsel & Corporation Sec. 9,867 $8.59 $84,758

What does Anika Therapeutics, Inc. do?

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

ANIK logo
ANIK
Anika Therapeutics, Inc.
$8.59

David Colleran insider trading

Anika Therapeutics, Inc.

Transaction Date Security Shares Price per share Total value Source
Option
Restricted Stock Unit 5,465 N/A N/A
Option
Restricted Stock Unit 3,682 N/A N/A
Option
Common Stock 7,662 N/A N/A
Option
Common Stock 5,465 N/A N/A
Option
Common Stock 3,682 N/A N/A
Option
Restricted Stock Unit 7,662 N/A N/A
Option
Common Stock 7,663 N/A N/A
Option
Restricted Stock Unit 7,663 N/A N/A
Option
Common Stock 3,683 N/A N/A
Option
Restricted Stock Unit 3,683 N/A N/A
Option
Restricted Stock Unit 2,500 N/A N/A
Option
Common Stock 2,500 N/A N/A
Purchase
Common Stock 1,500 $21.37 $32,055
Purchase
Common Stock 1,500 $26.65 $39,978
Option
Common Stock 3,682 N/A N/A
Option
Restricted Stock Unit 3,682 N/A N/A
Option
Restricted Stock Unit 2,500 N/A N/A
Option
Common Stock 2,500 N/A N/A
Option
Common Stock 2,500 N/A N/A
Option
Restricted Stock Unit 2,500 N/A N/A

Anika Therapeutics key executives

Anika Therapeutics, Inc. executives and other stock owners filed with the SEC: